Study population

Patients with T2-T3N0M0 unifocal bladder cancer of any histologic subtype scheduled to receive radical daily bladder radiotherapy on the MR-linac were considered eligible. Patients were consented to a prospective single centre clinical research and ethics committee approved study (Prospective Evaluation of Radiotherapy Using Magnetic Resonance Image Guided Treatment, PERMIT; {"type":"clinical-trial","attrs":{"text":"NCT03727698","term_id":"NCT03727698"}}NCT03727698) conducted in accordance with Good Clinical Practice and The Declaration of Helsinki. Radiotherapy was delivered on the Elekta Unity MR-linac system (Elekta AB, Stockholm, Sweden) with concomitant chemotherapy (weekly gemcitabine 75 mg/m²).